Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

PURPOSE: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Lin, Nancy U., Borges, Virginia, Anders, Carey, Murthy, Rashmi K., Paplomata, Elisavet, Hamilton, Erika, Hurvitz, Sara, Loi, Sherene, Okines, Alicia, Abramson, Vandana, Bedard, Philippe L., Oliveira, Mafalda, Mueller, Volkmar, Zelnak, Amelia, DiGiovanna, Michael P., Bachelot, Thomas, Chien, A. Jo, O’Regan, Ruth, Wardley, Andrew, Conlin, Alison, Cameron, David, Carey, Lisa, Curigliano, Giuseppe, Gelmon, Karen, Loibl, Sibylle, Mayor, JoAl, McGoldrick, Suzanne, An, Xuebei, Winer, Eric P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403000/
https://ncbi.nlm.nih.gov/pubmed/32468955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00775
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados